High calcium diet alleviates 5/6 nephrectomy-induced bone deteriorations of lumbar vertebrae in mice

Hou,Hai‑Tao; Wang,Ya‑Nan; Shao,Shi‑Ze; Fu,Song; Huang,Xiang‑Peng; Wang,Xiao‑Hui

doi:10.3892/etm.2018.5866

High calcium diet alleviates 5/6 nephrectomy-induced bone deteriorations of lumbar vertebrae in mice

Authors:
- Hai‑Tao Hou
- Ya‑Nan Wang
- Shi‑Ze Shao
- Song Fu
- Xiang‑Peng Huang
- Xiao‑Hui Wang
View Affiliations

Affiliations: Department of Spinal and Spinal Cord Surgery, Shandong Wendeng Orthopedic Hospital, Wendeng, Shandong 264400, P.R. China
Published online on: February 14, 2018 https://doi.org/10.3892/etm.2018.5866
Pages: 3483-3488

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dietary calcium (Ca) supplementation has beneficial effects on bone health. However, it is not clear whether a high calcium diet (HCD) following 5/6 nephrectomy (5/6 Nx) is beneficial to bone health. The aim of the present study was to examine the effects of an HCD on bone metabolism using a chronic kidney disease (CKD) mouse model. Male C57BL/6J mice were divided into three groups: Sham group, 5/6 Nx group and 5/6 Nx + HCD group. Mice were sacrificed 12 weeks post‑surgery. Calcium (Ca) and creatinine (Cr) were measured using standard colorimetric methods and picric acid methods, respectively. Bone metabolism‑associated markers, FGF‑23, PTH, ALP‑b and TRAP‑5b were measured using ELISA kits. Lumbar vertebrae histomorphological analysis was performed using hematoxylin and eosin staining. The expression of osteoprotegerin (OPG) and receptor activator of nuclear factor κB ligand (RANKL) mRNA was detected using reverse transcription‑quantitative polymerase chain reaction. Impaired renal function and histopathological damage was indicated in 5/6 Nx mice. However, HCD had no significant effects on these changes in 5/6 Nx mice. Notably, mineral metabolism disorder and histopathological damage to lumbar vertebrae were markedly improved in HCD‑treated 5/6 Nx mice. Compared with 5/6 Nx mice, HCD supplementation significantly elevated the ratio of OPG/RANKL and inhibited RANKL mRNA expression in lumbar vertebrae. To conclude, the present findings indicated that increased Ca intake is effective in increasing bone mineral content of the lumbar vertebrae in 5/6 Nx mice. These results may provide a basis for the clinical use of dietary Ca supplementation as a therapeutic approach to treat CKD‑induced disturbance of mineral metabolism and bone loss.

View Figures

View References

1	Lin W, Li Y, Chen F, Yin S, Liu Z and Cao W: Klotho preservation via histone deacetylase inhibition attenuates chronic kidney disease-associated bone injury in mice. Sci Rep. 7:461952017. View Article : Google Scholar : PubMed/NCBI
2	Kochanek M, Said A and Lerma EV: Mineral metabolism in chronic kidney disease. Dis Mon. 61:425–433. 2015. View Article : Google Scholar : PubMed/NCBI
3	Naylor KL, McArthur E, Leslie WD, Fraser LA, Jamal SA, Cadarette SM, Pouget JG, Lok CE, Hodsman AB, Adachi JD and Garg AX: The three-year incidence of fracture in chronic kidney disease. Kidney Int. 86:810–818. 2014. View Article : Google Scholar : PubMed/NCBI
4	El Desoky S, Farag YM, Safdar E, Shalaby MA, Singh AK and Kari JA: Prevalence of hyperparathyroidism, mineral and bone disorders in children with advanced chronic kidney disease. Indian J Pediatr. 83:420–425. 2016. View Article : Google Scholar : PubMed/NCBI
5	Song Q and Sergeev IN: Calcium and vitamin D in obesity. Nutr Res Rev. 25:130–141. 2012. View Article : Google Scholar : PubMed/NCBI
6	Johnston CC Jr, Miller JZ, Slemenda CW, Reister TK, Hui S, Christian JC and Peacock M: Calcium supplementation and increases in bone mineral density in children. N Engl J Med. 327:82–87. 1992. View Article : Google Scholar : PubMed/NCBI
7	Lee WT, Leung SS, Wang SH, Xu YC, Zeng WP, Lau J, Oppenheimer SJ and Cheng JC: Double-blind, controlled calcium supplementation and bone mineral accretion in children accustomed to a low-calcium diet. Am J Clin Nutr. 60:744–750. 1994. View Article : Google Scholar : PubMed/NCBI
8	Katsumata S, Matsuzaki H, Uehara M and Suzuki K: Effects of dietary calcium supplementation on bone metabolism, kidney mineral concentrations, and kidney function in rats fed a high-phosphorus diet. J Nutr Sci Vitaminol (Tokyo). 61:195–200. 2015. View Article : Google Scholar : PubMed/NCBI
9	Song Q and Sergeev IN: High vitamin D and calcium intakes increase bone mineral (Ca and P) content in high-fat diet-induced obese mice. Nutr Res. 35:146–154. 2015. View Article : Google Scholar : PubMed/NCBI
10	Ferrari GO, Ferreira JC, Cavallari RT, Neves KR, dos Reis LM, Dominguez WV, Oliveira EC, Graciolli FG, Passlick-Deetjen J, Jorgetti V and Moysés RM: Mineral bone disorder in chronic kidney disease: Head-to-head comparison of the 5/6 nephrectomy and adenine models. BMC Nephrol. 15:692014. View Article : Google Scholar : PubMed/NCBI
11	Heveran CM, Ortega AM, Cureton A, Clark R, Livingston EW, Bateman TA, Levi M, King KB and Ferguson VL: Moderate chronic kidney disease impairs bone quality in C57Bl/6J mice. Bone. 86:1–9. 2016. View Article : Google Scholar : PubMed/NCBI
12	Souza AC, Tsuji T, Baranova IN, Bocharov AV, Wilkins KJ, Street JM, Alvarez-Prats A, Hu X, Eggerman T, Yuen PS and Star RA: TLR4 mutant mice are protected from renal fibrosis and chronic kidney disease progression. Physiol Rep. 3:e125582015. View Article : Google Scholar : PubMed/NCBI
13	Löwe A, Breuer J and Palkowitsch P: Evaluation of the effect of two gadolinium-containing contrast-enhancing agents, gadobutrol and gadoxetate disodium, on colorimetric calcium determinations in serum and plasma. Invest Radiol. 46:366–369. 2011. View Article : Google Scholar : PubMed/NCBI
14	Massoomi F, Mathews HG III and Destache CJ: Effect of seven fluoroquinolones on the determination of serum creatinine by the picric acid and enzymatic methods. Ann Pharmacother. 27:586–588. 1993. View Article : Google Scholar : PubMed/NCBI
15	Sun D, Feng J, Dai C, Sun L, Jin T, Ma J and Wang L: Role of peritubular capillary loss and hypoxia in progressive tubulointerstitial fibrosis in a rat model of aristolochic acid nephropathy. Am J Nephrol. 26:363–371. 2006. View Article : Google Scholar : PubMed/NCBI
16	Fan HY, Qi D, Yu C, Zhao F, Liu T, Zhang ZK, Yang MY, Zhang LM, Chen DQ and Du Y: Paeonol protects endotoxin-induced acute kidney injury: Potential mechanism of inhibiting TLR4-NF-kappaB signal pathway. Oncotarget. 7:39497–39510. 2016. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Kakareko K, Rydzewska-Rosolowska A, Brzosko S, Gozdzikiewicz-Lapinska J, Koc-Zorawska E, Samocik P, Kozlowski R, Mysliwiec M, Naumnik B and Hryszko T: The effect of nephrectomy on Klotho, FGF-23 and bone metabolism. Int Urol Nephrol. 49:681–688. 2017. View Article : Google Scholar : PubMed/NCBI
19	Nitta K, Nagano N and Tsuchiya K: Fibroblast growth factor 23/klotho axis in chronic kidney disease. Nephron Clin Pract. 128:1–10. 2014. View Article : Google Scholar : PubMed/NCBI
20	Christov M, Waikar SS, Pereira RC, Havasi A, Leaf DE, Goltzman D, Pajevic PD, Wolf M and Jüppner H: Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int. 84:776–785. 2013. View Article : Google Scholar : PubMed/NCBI
21	Lavi-Moshayoff V, Wasserman G, Meir T, Silver J and Naveh-Many T: PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: A bone parathyroid feedback loop. Am J Physiol Renal Physiol. 299:F882–F889. 2010. View Article : Google Scholar : PubMed/NCBI
22	Wu Y, Lee JW, Uy L, Abosaleem B, Gunn H, Ma M and DeSilva B: Tartrate-resistant acid phosphatase (TRACP 5b): A biomarker of bone resorption rate in support of drug development: Modification, validation and application of the BoneTRAP kit assay. J Pharm Biomed Anal. 49:1203–1212. 2009. View Article : Google Scholar : PubMed/NCBI
23	An J, Yang H, Zhang Q, Liu C, Zhao J, Zhang L and Chen B: Natural products for treatment of osteoporosis: The effects and mechanisms on promoting osteoblast-mediated bone formation. Life Sci. 147:46–58. 2016. View Article : Google Scholar : PubMed/NCBI
24	Haussler MR, Whitfield GK, Kaneko I, Forster R, Saini R, Hsieh JC, Haussler CA and Jurutka PW: The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis. Rev Endocr Metab Disord. 13:57–69. 2012. View Article : Google Scholar : PubMed/NCBI
25	Martin A and Quarles LD: Evidence for FGF23 involvement in a bone-kidney axis regulating bone mineralization and systemic phosphate and vitamin D homeostasis. Adv Exp Med Biol. 728:65–83. 2012. View Article : Google Scholar : PubMed/NCBI
26	Pitari MR, Rossi M, Amodio N, Botta C, Morelli E, Federico C, Gullà A, Caracciolo D, Di Martino MT, Arbitrio M, et al: Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts. Oncotarget. 6:27343–27358. 2015. View Article : Google Scholar : PubMed/NCBI
27	Walsh MC and Choi Y: Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond. Front Immunol. 5:5112014. View Article : Google Scholar : PubMed/NCBI
28	Hill Gallant KM and Spiegel DM: Calcium balance in chronic kidney disease. Curr Osteoporos Rep. 15:214–221. 2017. View Article : Google Scholar : PubMed/NCBI
29	Hill KM, Martin BR, Wastney ME, McCabe GP, Moe SM, Weaver CM and Peacock M: Oral calcium carbonate affects calcium but not phosphorus balance in stage 3–4 chronic kidney disease. Kidney Int. 83:959–966. 2013. View Article : Google Scholar : PubMed/NCBI
30	Bosworth C, de Boer IH, Targher G, Kendrick J, Smits G and Chonchol M: The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. Clin Nephrol. 77:358–365. 2012. View Article : Google Scholar : PubMed/NCBI
31	Charoenphandhu N, Tudpor K, Thongchote K, Saengamnart W, Puntheeranurak S and Krishnamra N: High-calcium diet modulates effects of long-term prolactin exposure on the cortical bone calcium content in ovariectomized rats. Am J Physiol Endocrinol Metab. 292:E443–E452. 2007. View Article : Google Scholar : PubMed/NCBI
32	Fonseca D and Ward WE: Daidzein together with high calcium preserve bone mass and biomechanical strength at multiple sites in ovariectomized mice. Bone. 35:489–497. 2004. View Article : Google Scholar : PubMed/NCBI
33	Naitoh M, Takada ST, Kurosu Y, Inagaki K, Mitani A and Ariji E: Relationship between findings of mandibular cortical bone in inferior border and bone mineral densities of lumbar vertebrae in postmenopausal women. Okajimas Folia Anat Jpn. 91:49–55. 2014. View Article : Google Scholar : PubMed/NCBI
34	Naylor KL, Lix LM, Hans D, Garg AX, Rush DN, Hodsman AB and Leslie WD: Trabecular bone score in kidney transplant recipients. Osteoporos Int. 27:1115–1121. 2016. View Article : Google Scholar : PubMed/NCBI
35	van Heerden B, Kasonga A, Kruger MC and Coetzee M: Palmitoleic acid inhibits RANKL-induced osteoclastogenesis and bone resorption by suppressing NF-kappaB and MAPK signalling pathways. Nutrients. 9:E4412017. View Article : Google Scholar : PubMed/NCBI
36	Piri F, Khosravi A, Moayeri A, Moradipour A and Derakhshan S: The effects of dietary supplements of calcium, vitamin D and estrogen hormone on serum levels of OPG and RANKL cytokines and their relationship with increased bone density in Rats. J Clin Diagn Res. 10:AF01–AF04. 2016.PubMed/NCBI
37	Stubbs J, Liu S and Quarles LD: Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial. 20:302–308. 2007. View Article : Google Scholar : PubMed/NCBI
38	David V, Dai B, Martin A, Huang J, Han X and Quarles LD: Calcium regulates FGF-23 expression in bone. Endocrinology. 154:4469–4482. 2013. View Article : Google Scholar : PubMed/NCBI
39	Rodriguez-Ortiz ME, Lopez I, Muñoz-Castañeda JR, Martinez-Moreno JM, Ramírez AP, Pineda C, Canalejo A, Jaeger P, Aguilera-Tejero E, Rodriguez M, et al: Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol. 23:1190–1197. 2012. View Article : Google Scholar : PubMed/NCBI
40	Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M and Quarles LD: Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 17:1305–1315. 2006. View Article : Google Scholar : PubMed/NCBI
41	Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, et al: FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int. 65:1943–1946. 2004. View Article : Google Scholar : PubMed/NCBI
42	Penido MGMG and Alon US: Phosphate homeostasis and its role in bone health. Pediatr Nephrol. 27:2039–2048. 2012. View Article : Google Scholar : PubMed/NCBI
43	Nickolas TL and Jamal SA: Bone kidney interactions. Rev Endocr Metab Disord. 16:157–163. 2015. View Article : Google Scholar : PubMed/NCBI
44	Spiegel DM and Brady K: Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int. 81:1116–1122. 2012. View Article : Google Scholar : PubMed/NCBI